Literature DB >> 7231154

Immune complexes, complement, and anti-DNA in exacerbations of systemic lupus erythematosus (SLE).

W Lloyd, P H Schur.   

Abstract

The usefulness of serological parameters in assessing clinical exacerbations of SLE was examined. Patients with active renal disease tend to have lower levels of CH50 and C3 and highest levels of immune complexes detected by C1qBA than those patients with extrarenal manifestations only. Patients with a combination of both active extrarenal and renal disease are more likely to demonstrate the lowest levels of CH50, C4, and C3. However, immune complex levels are not higher than levels detected in patients with only active nephritis. A normal C3 level argues against active nephritis. Low complement levels without appreciably elevated levels of C1qBA suggest that significant renal disease is unlikely. The serial measurements that best reflect evolving clinical activity and which may serve as markers of impending exacerbation are, in decreasing order of usefulness: C4, CH50, C1qBA, C4, C3 and ADA. However, a combination of CH50, C4, C3 and C1qBA appeared to be the most useful. Given various serologic changes, guidelines for following patients are offered.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7231154     DOI: 10.1097/00005792-198105000-00004

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  61 in total

Review 1.  Complement as a source of biomarkers in systemic lupus erythematosus: past, present, and future.

Authors:  Chau-Ching Liu; Joseph M Ahearn; Susan Manzi
Journal:  Curr Rheumatol Rep       Date:  2004-04       Impact factor: 4.592

2.  Evaluation of serum levels of soluble interleukin-2 receptor as an indicator of disease activity in systemic lupus erythematosus.

Authors:  P Airŏ; S Braga; E Prati; D Brugnoni; M Bettinzioli; R Gorla; R Cattaneo
Journal:  Clin Rheumatol       Date:  1992-03       Impact factor: 2.980

Review 3.  Systemic lupus erythematosus: RNA-protein autoantigens, models of disease heterogeneity, and theories of etiology.

Authors:  J B Harley; R H Scofield
Journal:  J Clin Immunol       Date:  1991-11       Impact factor: 8.317

4.  Urine free light chains in SLE: clonal markers of B-cell activity and potential link to in vivo secreted Ig.

Authors:  J E Hopper; J Golbus; C Meyer; G A Ferrer
Journal:  J Clin Immunol       Date:  2000-03       Impact factor: 8.317

Review 5.  Anti-DNA antibodies as early predictor for disease exacerbations in SLE. Guideline for treatment?

Authors:  P E Spronk; H Bootsma; C G Kallenberg
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

6.  Correlation of the activation of the fourth component of complement (C4) with disease activity in systemic lupus erythematosus.

Authors:  G Senaldi; V A Makinde; D Vergani; D A Isenberg
Journal:  Ann Rheum Dis       Date:  1988-11       Impact factor: 19.103

7.  Assessment of class-specific antibodies against denatured DNA in patients with systemic lupus erythematosus.

Authors:  M Gripenberg; M Leirisalo; E Johansson; G Gripenberg
Journal:  J Clin Immunol       Date:  1985-09       Impact factor: 8.317

8.  Anti-DNA antibodies of IgA class in patients with systemic lupus erythematosus.

Authors:  M Gripenberg; T Helve
Journal:  Rheumatol Int       Date:  1986       Impact factor: 2.631

9.  C4a anaphylatoxin levels as an indicator of disease activity in systemic lupus erythematosus.

Authors:  G Wild; J Watkins; A M Ward; P Hughes; A Hume; N R Rowell
Journal:  Clin Exp Immunol       Date:  1990-05       Impact factor: 4.330

10.  Pulsed methylprednisolone therapy compared to high dose prednisone in systemic lupus erythematosus nephritis.

Authors:  E H Garin; J W Sleasman; G A Richard; A A Iravani; R S Fennell
Journal:  Eur J Pediatr       Date:  1986-10       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.